Cliff Asness's BSX Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 1.1 M shares of Boston Scientific Corporation (BSX) worth $104.67 M, representing 0.05% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 53 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in BSX, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2013, adding 8.01 M shares. Largest reduction occurred in Q3 2014, reducing 6.79 M shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Boston Scientific Corporation (BSX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Boston Scientific Corporation (BSX) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -74,106 | Reduce 6.32% | 1.1 M | $95.35 |
| Q3 2025 | -671,342 | Reduce 36.42% | 1.17 M | $97.63 |
| Q2 2025 | +687,364 | Add 59.47% | 1.84 M | $106.94 |
| Q1 2025 | +243,893 | Add 26.74% | 1.16 M | $99.00 |
| Q4 2024 | -53,014 | Reduce 5.49% | 911,936 | $89.32 |
| Q3 2024 | +262,732 | Add 37.41% | 964,950 | $83.27 |
| Q2 2024 | -151,474 | Reduce 17.74% | 702,218 | $76.75 |
| Q1 2024 | +42,585 | Add 5.25% | 853,692 | $68.49 |
| Q4 2023 | +273,955 | Add 51.00% | 811,107 | $57.25 |
| Q3 2023 | +68,478 | Add 14.61% | 537,152 | $52.80 |
| Q2 2023 | +208,267 | Add 79.98% | 468,674 | $54.09 |
| Q1 2023 | +33,335 | Add 14.68% | 260,407 | $50.03 |
| Q4 2022 | +30,797 | Add 15.69% | 227,072 | $46.00 |
| Q3 2022 | +56,342 | Add 40.26% | 196,275 | $38.73 |
| Q2 2022 | +5,386 | Add 4.00% | 139,933 | $37.17 |
| Q1 2022 | -191,259 | Reduce 58.70% | 134,547 | $44.29 |
| Q4 2021 | -49,312 | Reduce 13.15% | 325,806 | $42.48 |
| Q3 2021 | -101,272 | Reduce 21.26% | 375,118 | $43.39 |
| Q2 2021 | -307,364 | Reduce 39.22% | 476,390 | $42.76 |
| Q1 2021 | -764,411 | Reduce 49.38% | 783,754 | $38.65 |
| Q4 2020 | +998,933 | Add 181.88% | 1.55 M | $35.58 |
| Q3 2020 | -248,356 | Reduce 31.14% | 549,232 | $37.82 |
| Q2 2020 | +392,667 | Add 96.97% | 797,588 | $34.33 |
| Q1 2020 | +161,806 | Add 66.56% | 404,921 | $32.63 |
| Q4 2019 | -82,479 | Reduce 25.33% | 243,115 | $45.22 |
| Q3 2019 | -1.06 M | Reduce 76.57% | 325,594 | $40.69 |
| Q2 2019 | -977,065 | Reduce 41.28% | 1.39 M | $42.06 |
| Q1 2019 | +629,852 | Add 36.26% | 2.37 M | $38.14 |
| Q4 2018 | -708,505 | Reduce 28.97% | 1.74 M | $35.34 |
| Q3 2018 | -217,266 | Reduce 8.16% | 2.45 M | $38.50 |
| Q2 2018 | -190,288 | Reduce 6.67% | 2.66 M | $32.70 |
| Q1 2018 | +92,265 | Add 3.34% | 2.85 M | $27.32 |
| Q4 2017 | +1.43 M | Add 106.73% | 2.76 M | $24.79 |
| Q3 2017 | -451,507 | Reduce 25.27% | 1.34 M | $29.17 |
| Q2 2017 | -375,428 | Reduce 17.36% | 1.79 M | $27.72 |
| Q1 2017 | -395,304 | Reduce 15.46% | 2.16 M | $24.87 |
| Q4 2016 | +29,528 | Add 1.17% | 2.56 M | $21.63 |
| Q3 2016 | +1.54 M | Add 156.71% | 2.53 M | $23.80 |
| Q2 2016 | -171,288 | Reduce 14.82% | 984,820 | $23.37 |
| Q1 2016 | -1.1 M | Reduce 48.83% | 1.16 M | $18.81 |
| Q4 2015 | -2.19 M | Reduce 49.17% | 2.26 M | $18.44 |
| Q3 2015 | +2.07 M | Add 87.13% | 4.45 M | $16.41 |
| Q2 2015 | +911,244 | Add 62.23% | 2.38 M | $17.70 |
| Q1 2015 | -1.52 M | Reduce 50.94% | 1.46 M | $17.75 |
| Q4 2014 | -1.9 M | Reduce 38.92% | 2.98 M | $13.25 |
| Q3 2014 | -6.79 M | Reduce 58.17% | 4.89 M | $11.81 |
| Q2 2014 | +80,300 | Add 0.69% | 11.68 M | $12.77 |
| Q1 2014 | -459,600 | Reduce 3.81% | 11.6 M | $13.52 |
| Q4 2013 | +887,984 | Add 7.95% | 12.06 M | $12.02 |
| Q3 2013 | -1.08 M | Reduce 8.84% | 11.17 M | $11.74 |
| Q2 2013 | +12.26 M | Add 0.00% | 12.26 M | $9.27 |
| Q4 2012 | +4.24 M | Add 0.00% | 4.24 M | $5.73 |
Cliff Asness's Boston Scientific Corporation Investment FAQs
Cliff Asness first purchased Boston Scientific Corporation (BSX) in Q4 2012, acquiring 4,243,400 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Boston Scientific Corporation (BSX) for 53 quarters since Q4 2012.
Cliff Asness's largest addition to Boston Scientific Corporation (BSX) was in Q2 2013, adding 12,257,300 shares worth $113.62 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 1,097,745 shares of Boston Scientific Corporation (BSX), valued at approximately $104.67 M.
As of the Q4 2025 filing, Boston Scientific Corporation (BSX) represents approximately 0.05% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Boston Scientific Corporation (BSX) was 12,257,300 shares, as reported at the end of Q2 2013.